Mission Bio’s Tapestri Platform Can Now Identify Both Mutations and Copy Number Variants from the Same Cells
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Mission Bio, Inc., the pioneer in targeted single-cell DNA analysis and precision genomics, announced the launch of Copy Number Analysis, extending Copy Number Variation (CNV) capabilities to its Tapestri Platform with no changes to the current workflow. With this latest capability, Mission Bio’s Tapestri® Platform now stands as the first and only commercial platform for single-cell DNA analysis, with comprehensive insight into mutations and CNVs from the same cell on a single platform, expanding the company’s leadership in single-cell DNA analysis for oncology.
CNVs, where portions of the chromosome are amplified or deleted, are the cause of many genetic disorders and are present in 45 percent of cancers. When determining the clonal heterogeneity across a cancer sample, it’s important to comprehensively measure both DNA mutations and copy number alterations in every cell because disease progression and therapy response are based on differences in genetic alterations across cells. This includes both single nucleotide variations (SNVs), which are prognostic and provide insight into the disease development and progression, and CNVs, which tend to predict the severity of the disease.
“Access to both SNVs and CNVs at the single-cell level, from the same cell, gives us higher resolution to explore tumor evolution and disease progression,” said Samra Turajlic, M.D., of Francis Crick Institute. “We look forward to analyzing these novel data types to help us better resolve the genetic and cellular heterogeneity in cancer.”
Mission Bio’s high-throughput single-cell DNA analysis on the Tapestri Platform yields unprecedented insight into the diversity of genomic changes found in individual cancer cells. Moreover, for the first time, CNVs and SNVs can be measured from the same single cell across thousands of cells. With the Tapestri Platform, researchers and clinicians can now leverage a single platform to measure nearly every type of DNA change in every diseased cell. This results in significant cost savings and improved workflow, all while enabling even deeper insight into patterns of tumor evolution, therapy response, and resistance.
“The ability to pair mutations and gene-level to chromosome-level copy number from the same cell has never before been available for single-cell DNA analysis, let alone on a single platform,” said Nigel Beard, SVP of Research and Development (R&D) at Mission Bio. “With the launch of Copy Number Analysis on the Tapestri Platform, we’re enabling the full picture of any variation at the DNA level, giving unprecedented insights that will accelerate cancer research and enable precision medicine.”
Mission Bio has demonstrated the Tapestri Platform’s ability to track and monitor cancer evolution with single-cell precision with numerous peer-reviewed studies, including the most recent in Cancer Discovery, which examined the Tapestri Platform’s use in Acute Myeloid Leukemia (AML) research.
CNVs, where portions of the chromosome are amplified or deleted, are the cause of many genetic disorders and are present in 45 percent of cancers. When determining the clonal heterogeneity across a cancer sample, it’s important to comprehensively measure both DNA mutations and copy number alterations in every cell because disease progression and therapy response are based on differences in genetic alterations across cells. This includes both single nucleotide variations (SNVs), which are prognostic and provide insight into the disease development and progression, and CNVs, which tend to predict the severity of the disease.
“Access to both SNVs and CNVs at the single-cell level, from the same cell, gives us higher resolution to explore tumor evolution and disease progression,” said Samra Turajlic, M.D., of Francis Crick Institute. “We look forward to analyzing these novel data types to help us better resolve the genetic and cellular heterogeneity in cancer.”
Mission Bio’s high-throughput single-cell DNA analysis on the Tapestri Platform yields unprecedented insight into the diversity of genomic changes found in individual cancer cells. Moreover, for the first time, CNVs and SNVs can be measured from the same single cell across thousands of cells. With the Tapestri Platform, researchers and clinicians can now leverage a single platform to measure nearly every type of DNA change in every diseased cell. This results in significant cost savings and improved workflow, all while enabling even deeper insight into patterns of tumor evolution, therapy response, and resistance.
“The ability to pair mutations and gene-level to chromosome-level copy number from the same cell has never before been available for single-cell DNA analysis, let alone on a single platform,” said Nigel Beard, SVP of Research and Development (R&D) at Mission Bio. “With the launch of Copy Number Analysis on the Tapestri Platform, we’re enabling the full picture of any variation at the DNA level, giving unprecedented insights that will accelerate cancer research and enable precision medicine.”
Mission Bio has demonstrated the Tapestri Platform’s ability to track and monitor cancer evolution with single-cell precision with numerous peer-reviewed studies, including the most recent in Cancer Discovery, which examined the Tapestri Platform’s use in Acute Myeloid Leukemia (AML) research.
